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Declining Childhood and Adolescent Cancer Mortality
Great Progress but Still Much to Be Done
Kathy Pritchard-Jones, BM BCh, PhD, FRCPCH1 and Darren Hargrave, MB, ChB (Hons), MD, MRCP, FRCPCH2
In this issue of Cancer, Smith et al report on mortality rates for children and adolescents with cancer from 1975 to 2010.1
They focused on the most recent period between 2002 and 2010 and demonstrated a rate of decline in mortality similar to
that observed from 1975 to 1998 after an apparent plateau between 1998 and 2002. An annual percentage change (APC)
in mortality rate of 2.4% was observed across both adolescents and children, with the most significant reductions reported
in acute leukemias, lymphomas, neuroblastoma, gonadal cancers, and some central nervous system tumors. Increased sur-
vival rather than any change in incidence appears to explain the decreased mortality. The authors estimated that 45,000
cancer deaths have been avoided between 1975 and 2010 because of this sustained improvement.
The main strength of the article is the 35-year duration of mortality data from a significant proportion of the United
States derived from the US Centers for Disease Control and Prevention. Survival estimates were derived from the Surveil-
lance, Epidemiology, and End Results (SEER) 9 registries. Similar population-based analyses of mortality and survival for
European children have been reported recently, allowing us to highlight comparisons that may aid in the interpretation of
the findings.2,3 Bosetti et al used a similar joinpoint analysis method to assess trends in mortality rates for European child-
hood cancer over the period from 1970 to 2007. This demonstrated a continuous decline in mortality rates throughout
the period of analysis, with an APC between 2% and 4% for all cancers combined and between 3% and 6% separately for
leukemias. Although those authors did not comment on any obvious plateau in the rate of decline, there was considerable
geographic variation in mortality and rates of change.
Two important messages emerge from the article by Smith et al. The first is that improvements in childhood cancer
mortality and survival rates have continued in recent years, but the rate of progress has been greater in hematologic malig-
nances than in solid tumors. This differential rate of improvement has been observed in both the United States and
Europe, and the cancer types that have made the major contribution to increased survival rates are acute lymphoblastic leu-
kemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin lymphoma (NHL). Here, the survival rates are compara-
ble between the United States and the best of the European geographic regions (eg Northern and Central Europe).
Unfortunately, there has been no significant improvement in survival for high-grade glioma and metastatic sarcomas on
either continent. However, there are some notable differences, with the US data reporting significant improvements in
5-year relative survival in neuroblastoma and Hodgkin lymphoma that have yet to be observed across Europe.
The second important message is that these improvements in mortality and survival also have been observed in ado-
lescents. Progress in adolescent cancer mortality has been impressive and indeed superior to that of children during the
same time frame. This is despite data suggesting that adolescents and young adults did not have the same opportunity of
being enrolled onto clinical trials with a possible disadvantage in outcome.4,5 This disparity may be caused in part by a dif-
ferent spectrum of malignancies, eg germ cell tumors, lymphoma, and leukemia, and because these cancers have benefited
from survival increases as a result of previous successful clinical trial protocols that have now been adopted as standard
therapies, with the result that adolescents and young adults are increasingly being treated either as part of a clinical trial or
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within units familiar with their administration, eg pediat-
ric ALL protocols. However, it is vital that the opportu-
nity to be enrolled onto suitable cooperative trials is
extended to as many malignances as possible that affect
teenagers and young adults by facilitating appropriate
referral pathways.6
There are some limitations to the study of Smith
and colleagues that should be considered when interpret-
ing the data. The SEER 9 registry data cover only 10% of
the United States, and it must be asked whether the data
presented represent the whole US population. Further-
more, additional new data for the period from 2007 to
2010 has resulted in the emergence of new plateaus in the
joinpoint analyses of earlier periods that were not
observed in the initial publication, thus casting some
doubt on the reproducibility of the findings. However, a
similar deceleration in the rate of improvement has also
been observed in some European mortality data, particu-
larly in Northern andWestern European countries, where
the plateau appears to be continuing.2,7 By contrast, the
presented US data demonstrate a further improvement in
the most recent period studied from 2003 onward. Smith
et al interpret these trends in the APC for mortality rates
as a reflection of several years in which more effective
treatments were not identified or broadly adopted for
childhood cancers, but they offer no further explanation
why the newly identified plateau spanning the period
from 1998 through 2002 differs either from the preceding
or subsequent US data or indeed in a comparison with
European data. It would have been interesting to explore
any correlation between clinical trial activity during the
various periods studied and mortality and survival rates, as
was published by the UK group.8 Details on cause of
death would be valuable to determine whether improve-
ments also may have been related to better supportive care
and a reduction in the treatment-related mortality rate, a
relevant factor in allowing treatment intensification.
Smith et al also report on improvements in relative
survival from the SEER registries, demonstrating an esti-
mated 5-year survival rate for all cancers combined of
almost 84% for children and adolescents who were diag-
nosed between 2003 and 2007 and followed until 2010.
This is slightly better than the equivalent rate of 79.1%
for all childhood cancers diagnosed during 2005 to 2007
in Europe, as recently published by the EUROCARE-5
Childhood Cancer Survival Study. With participation
from 29 countries and 74 population-based cancer regis-
tries, the EUROCARE-5 study was able to demonstrate
the extent of geographic variation that may be observed,
an aspect that has not been addressed in the current analy-
sis of US data. Survival rates in the best performing Euro-
pean regions can match those reported in the United
States. Such regional variations in outcomes highlight the
importance of ensuring uniform population-level access
to best practice. Indeed, efforts to introduce European
standards of cancer care for children are in progress.9
However, making visible and then addressing inequalities
in outcomes for children and young patients with cancer
needs consideration on every continent.10
Over the last decade, concerns have been expressed
in high-income countries that clinical trials have almost
reached the limits for optimization of conventional surgi-
cal, radiotherapy, and cytotoxic-based therapies, with
minimal further improvements possible.7 Therefore, it is
reassuring that further reductions in mortality rates have
been achieved in the United States. It is important to fur-
ther explore the possible reasons behind these improve-
ments for all ages. Taking ALL as an example, it seems
unlikely that the most recent reductions in mortality and
increases in survival have been caused by the introduction
of novel targeted agents. It is more likely that the optimi-
zation of conventional therapies as a result of better
patient risk stratification has allowed more accurate selec-
tion of high-risk groups for appropriate intensification of
conventional therapies with a de-escalation of treatment
for selected low-risk groups.
This paradigm of risk stratification using combined
clinical, pathologic, and molecular biology data is being
used increasingly in some solid tumors (eg neuroblas-
toma, nephroblastoma, and medulloblastoma), but its
application is restricted to those solid tumors in which the
clinical significance of the underlying tumor biology is
well understood. Progress in this area has been slower and
more recent in solid tumors than in hematologic malig-
nancies, perhaps explaining the differential rate of
improvement. Another possible cause for mortality reduc-
tion and increased overall survival may be the more sys-
tematic use at relapse of second-line “salvage” protocols,
which, in some diseases, may have improved the 5-year
overall survival rate among patients who had relapsed
tumors that previously were considered incurable.11,12
In contrast to the continued improvements observed
in hematologic malignancies, the lack of any significant
reduction in mortality rates among patients with poor-
prognostic solid tumors (ie, high-risk brain tumors, meta-
static sarcomas, and neuroblastoma) remains a major con-
cern. Deaths from leukemia continue to be the second
largest cause of cancer deaths, and the identification of
high-risk subgroups and improved salvage therapies
remains a priority. Figure 1 illustrates the percentage
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contribution by category to all cancer deaths in children
ages birth to 14 years in all 50 areas covered by
population-based cancer registries that contributed data
for the years 2000 through 2007 to the European Cancer
Observatory. It is apparent from these data that the cause
of cancer death in the group aged<15 years is very similar
to that reported by Smith et al in the current study. This
highlights the need for international collaboration and a
refocusing of efforts on developing new treatment
approaches to tackle the major causes of childhood cancer
deaths if we are to witness further reductions in childhood
cancer mortality in the future. The US data suggest that
there have been modest improvements in survival among
children with neuroblastoma, but it is not clear whether
the survival gains demonstrated for high-risk neuroblas-
toma are a result of the introduction of immunotherapy
using the disialoganglioside 2 (GD2)-targeted chimeric
monoclonal antibody ch14.18.14 However, as an example
of a new cancer therapeutic approach, it is hoped that
immunotherapy may be a promising development not
only in neuroblastoma but also in other childhood malig-
nancies, such as treatment with chimeric antigen receptor-
modified T cells in ALL.15 It is unlikely that the introduc-
tion of biologically targeted therapies or molecular-based
risk stratification can explain the resumption of a decline
in US mortality rates from 2002 onward, because their
use is not yet widespread enough to affect mortality rates
at the population level. However, it is hoped that the rapid
expansion in knowledge of the underlying molecular eti-
ology of pediatric solid and central nervous system tumors
can translate into real survival benefits with the com-
mencement of molecular-stratified clinical trials, eg for
medulloblastoma.16
In addition to better risk stratification, the objective
of large-scale, consortia-based genomic studies is to iden-
tify and validate possible targetable mutations in pediatric
malignancy. The results to date have identified relatively
low frequencies of known actionable mutations, such as
ALK or BRAF mutations in childhood cancers.17-19 To
effectively study targeted agents against such low-
frequency mutations will require close cooperation
between academia, industry, and regulatory groups on a
global basis because of the rarity of patients harboring
these oncogenes.20 What is emerging from the interroga-
tion of the genome, epigenome, and transcriptome of pe-
diatric malignancies is the often distinctive and specific
underlying molecular changes of childhood cancers, eg
hedgehog pathway activation in some medulloblastomas
and histone and chromatin remodeling genes in pediatric
malignant and pontine gliomas.21-23 Some of these dis-
tinct targets already have novel agents developed against
them, eg smoothened inhibitors, and are moving from
early to later phase, biomarker-led clinical trials. However,
for many pediatric known and emerging targets, there are
no current targeted therapies, eg chromosomal transloca-
tions in sarcomas and MYCN in neuroblastoma, sarco-
mas, and medulloblastoma. The need to incentivize drug
development for childhood cancer has been recognized;
and, in both the United States and Europe, new regula-
tions and legislation have been introduced to engage
industry and encourage collaborations with the academic
community.20 However, these have been only partially
successful, and further adaptations and amendments will
be needed to produce a sufficient investment in knowl-
edge and funding to achieve the successful development
of possible novel, pediatric-specific therapies.24,25 In addi-
tion, it appears that the global community needs to refo-
cus on those tumors in which little progress has been
made in the past 3 or 4 decades, such as malignant gliomas
and metastatic sarcomas.
The data presented by Smith et al only describe mor-
tality and do not indicate the cause of death or, impor-
tantly, the burden of cure on the patient and society. A
major priority of pediatric oncology is not only to avoid as
many deaths as possible in children with cancer but also to
decrease the burden of treatment and to reduce both acute
and long-term toxicity. Quality of survivorship is vitally
Figure 1. Percentages of known causes among all cancer
deaths are illustrated in children (ages 0-14 years) for all 50
areas covered by population-based cancer registries that
contributed data for the years 2000 through 2007 to the Eu-
ropean Cancer Observatory (N56256).13 Causes of deaths
are classified according to the International Classification of
Diseases 10th edition. Note that endocrine gland tumor
deaths are in the majority among patients with neuroblas-
toma. CNS indicates central nervous system.
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important, and better risk stratification has led to a reduc-
tion in some toxic treatments for good-risk patients, eg
those with Hodgkin lymphoma and nephroblastoma, by
decreasing anthracycline and radiotherapy exposure. We
hope that novel targeted agents may decrease long-term
side effects by replacing conventional radiotherapy and
chemotherapy; however, care needs to be taken, because
many targeted pathways play important roles in normal
development, and new toxicities and side effects may
emerge in the acute and chronic settings. Therefore, it is
important that investment is made into whole outcome
research to estimate the burden of both existing and new
therapies with appropriate long-term, validated outcome
measures.
The report by Smith et al adds to data confirming
the continued progress in reducing cancer mortality
among both children and adolescents, and a short reflec-
tion on this achievement is warranted before we quickly
turn our attention to the remaining challenges. Now, we
need to ensure that every patient achieves the same out-
comes wherever they may live, that we reinvigorate our
efforts to improve survival in the cancers that kill the most
patients, and that we continue to decrease the burden of
treatment and improve the quality of survival for those we
cure.
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